{"product_id":"roche-pestle-analysis","title":"Roche  PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain actionable insight into how regulatory shifts, global healthcare spending, and rapid biotech innovation shape Roche’s strategic outlook with our concise PESTLE Analysis—ideal for investors and strategists seeking a competitive edge; purchase the full report for a complete, ready-to-use breakdown and instant download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS Drug Pricing Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Inflation Reduction Act’s drug pricing provisions are shaving growth: Medicare negotiations and rebates could reduce Roche’s U.S. biologics revenue by an estimated 3–7% annually, with negotiated price cuts targeting top oncology and immunology drugs and potential rebate liabilities exceeding $500m–$1bn per year for major portfolios; strategic shifts in pricing, launch sequencing and cost structure are required to protect North American margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Supply Chain Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent geopolitical tensions between the US, EU and China push Roche toward localized manufacturing and sourcing; Roche disclosed in 2024 that 18% of its active pharmaceutical ingredient spend was China-linked, prompting supply-chain reshoring programs to cut regional exposure by 25% by 2026.\u003c\/p\u003e\n\u003cp\u003eRoche must navigate export controls and tariff risks—China accounted for about 9% of 2023 group sales—requiring contingency stocks and alternative suppliers to ensure delivery of critical oncology and immunology therapies.\u003c\/p\u003e\n\u003cp\u003eDiversifying suppliers and increasing regional manufacturing capacity remain priorities after global disruptions in 2020–22; Roche targets a 15–20% diversification of key suppliers through 2025 to mitigate political instability and protectionist policies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEuropean Healthcare Austerity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMany European governments tightened healthcare budgets in 2025, with EU public health spending growth slowing to 0.8% year-on-year and several countries imposing drug cost caps; this forces Roche into complex value-based pricing negotiations to keep new therapies accessible.\u003c\/p\u003e\n\u003cp\u003eRoche must show clear clinical differentiation—e.g., demonstrating \u0026gt;20% absolute improvement or cost-per-QALY gains below national thresholds—to justify premium pricing within highly regulated public systems like NHS England and Germany’s SHI.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Regulatory Harmonization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cproche benefits from regulatory harmonization efforts and who initiatives have reduced duplicative reviews supporting faster entry into markets that represented over of its sales however divergent diagnostic validation standards in several emerging require additional local studies adding time cost. aligning clinical trial datasets with global helped roche cut multi-regional launch timelines by an estimated\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eICH\/WHO harmonization boosts multi-jurisdiction approvals\u003c\/li\u003e\n\u003cli\u003eEmerging-market diagnostic standards still demand local validation\u003c\/li\u003e\n\u003cli\u003eGlobal-standard aligned trials reduced launch time ~15%\u003c\/li\u003e\n\u003cli\u003eHarmonization supports access to regions comprising \u0026gt;60% of 2024 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/proche\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Infrastructure Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cppolitical commitments to strengthening healthcare infrastructure in developing nations by who and world bank financing of over major expansion opportunities for roche diagnostics scale lab capacity screening programs.\u003e\n\u003cproche capacity to form public partnerships enables deployment of diagnostics tapping markets with projected cagr\u003e6% in Sub‑Saharan Africa and Southeast Asia, while addressing unmet needs and strengthening brand presence.\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWHO\/World Bank infrastructure funding \u0026gt;$50bn (2023–2025)\u003c\/li\u003e\n\u003cli\u003eRoche leverages PPPs to expand labs and screening\u003c\/li\u003e\n\u003cli\u003eTarget regions proj. diagnostics CAGR \u0026gt;6%\u003c\/li\u003e\n\u003cli\u003ePPPs address unmet needs and build brand footprint\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/proche\u003e\u003c\/ppolitical\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche reshapes supply, pricing and PPPs as IRA cuts, EU caps and China exposure bite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical pressures—US IRA pricing cuts (3–7% U.S. biologics revenue impact; $500m–$1bn annual rebate risk), EU budget caps (public health spend growth 0.8% in 2025) and trade tensions—force Roche to localize supply (18% API China exposure in 2024; 25% regional reduction target by 2026) and pursue value‑based pricing and PPPs to protect access and margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIRA U.S. biologics impact\u003c\/td\u003e\n\u003ctd\u003e3–7% revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential rebates\u003c\/td\u003e\n\u003ctd\u003e$500m–$1bn\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI China exposure (2024)\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional sourcing reduction target\u003c\/td\u003e\n\u003ctd\u003e25% by 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU health spend growth (2025)\u003c\/td\u003e\n\u003ctd\u003e0.8% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Roche across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—each supported by data and current trends for reliable, actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented Roche PESTLE summary that distills regulatory, economic, technological, social, and environmental risks into one-slide-ready notes for quick team alignment and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwiss Franc Currency Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a Swiss-headquartered firm with ~60% of sales outside Europe, Roche is exposed to CHF appreciation versus USD\/EUR; a 10% CHF strengthening can cut reported CHF sales by roughly 5–7% based on 2024 currency mix. Currency headwinds dent export competitiveness for Switzerland-made diagnostics and pharma and pressured 2023–2024 reported operating profit margins. Roche’s 2024 hedge program and greater local sourcing in major markets aim to mitigate FX volatility, preserving EBIT and cash flow resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR and D Capital Allocation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe rising cost of drug development—estimated at about $2.6 billion per approved drug in 2020-2024 studies—forces Roche to allocate R and D capital selectively, balancing high-risk oncology and gene-therapy bets with lower-risk diagnostics; in 2024 Roche spent CHF 12.7 billion on R and D, about 20% of sales. Efficient research-budget management is vital as higher global interest rates raise capital costs and pressure ROI timelines. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Growth Dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSustained expansion in Southeast Asia and Latin America—GDP growth forecasts of ~4.5% and ~2.8% for 2025 respectively—is enlarging a middle class, boosting demand for Roche’s diagnostics and specialty drugs; emerging-market pharma spending rose about 6% YoY in 2024. Roche is localizing commercial strategies and launched region-specific pricing and distribution pilots in 2024 to capture this demand. Close monitoring of local inflation (e.g., 2024 avg. inflation: Brazil ~5.8%, Indonesia ~3.4%) informs sustainable pricing and margin management for these territories.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressure on Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePersistent inflation in energy and labor raised Roche’s manufacturing costs; global energy prices up ~15% in 2024 and Swiss wage growth ~3.5% pressured COGS, prompting automation investments to protect margins.\u003c\/p\u003e\n\u003cp\u003eRoche reported SG\u0026amp;A and R\u0026amp;D efficiencies in 2024, targeting \u0026gt;€1bn savings by 2026; with price controls limiting pass-through, internal cost optimization is essential to sustain operating margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnergy +15% (2024)\u003c\/li\u003e\n\u003cli\u003eSwiss wage growth ~3.5% (2024)\u003c\/li\u003e\n\u003cli\u003eTarget \u0026gt;€1bn savings by 2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilar Market Competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe entry of biosimilars for Herceptin and Rituxan has reduced Roche's sales exposure, with Herceptin global revenue falling from about CHF 6.6bn in 2018 to under CHF 1.5bn by 2023 and Rituxan similarly declining after 2018; Roche must accelerate late-stage launches (e.g., approved Tecentriq expansion, multiple Phase IIIs) to offset forecasted erosion of ~30–50% in off-patent biologic revenue within five years.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccelerate commercialization of late-stage pipeline to recoup CHF billions.\u003c\/li\u003e\n\u003cli\u003eLife-cycle management (label expansions, combination trials) to sustain revenues.\u003c\/li\u003e\n\u003cli\u003ePortfolio diversification into oncology\/immunology small molecules and diagnostics to mitigate 30–50% biosimilar-driven decline.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCHF strength trims sales 5–7%; CHF12.7bn R\u0026amp;D, cost pressures, \u0026gt;€1bn savings target\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCHF FX: 10% CHF strength → ~5–7% reported sales hit (2024 mix); 2024 hedge + local sourcing mitigate. R\u0026amp;D: CHF12.7bn (2024), development cost ≈$2.6bn per approved drug (2020–24 studies). Emerging markets: 2025 GDP forecasts SEA ~4.5%, LATAM ~2.8%; 2024 emerging-market pharma spend +6% YoY. Costs: energy +15% (2024), Swiss wages +3.5% (2024); target \u0026gt;€1bn savings by 2026.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eCHF12.7bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX impact\u003c\/td\u003e\n\u003ctd\u003e10% CHF ↑ → −5–7% sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy\u003c\/td\u003e\n\u003ctd\u003e+15% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWages (CH)\u003c\/td\u003e\n\u003ctd\u003e+3.5% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging market growth\u003c\/td\u003e\n\u003ctd\u003eSEA ~4.5%, LATAM ~2.8% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSavings target\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;€1bn by 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eRoche  PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Roche PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751291236729,"sku":"roche-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/roche-pestle-analysis.png?v=1772229830","url":"https:\/\/growthsharematrix.com\/products\/roche-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}